Nature Communications (Apr 2022)
Mitochondrially targeted tamoxifen alleviates markers of obesity and type 2 diabetes mellitus in mice
- Eliska Vacurova,
- Jaroslava Trnovska,
- Petr Svoboda,
- Vojtech Skop,
- Vendula Novosadova,
- David Pajuelo Reguera,
- Silvia Petrezselyová,
- Benoit Piavaux,
- Berwini Endaya,
- Frantisek Spoutil,
- Dagmar Zudova,
- Jan Stursa,
- Magdalena Melcova,
- Zuzana Bielcikova,
- Lukas Werner,
- Jan Prochazka,
- Radislav Sedlacek,
- Martina Huttl,
- Sona Stemberkova Hubackova,
- Martin Haluzik,
- Jiri Neuzil
Affiliations
- Eliska Vacurova
- Institute of Biotechnology, Czech Academy of Sciences
- Jaroslava Trnovska
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine
- Petr Svoboda
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine
- Vojtech Skop
- Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH
- Vendula Novosadova
- Institute of Molecular Genetics, Czech Academy of Sciences
- David Pajuelo Reguera
- Institute of Molecular Genetics, Czech Academy of Sciences
- Silvia Petrezselyová
- Institute of Molecular Genetics, Czech Academy of Sciences
- Benoit Piavaux
- Institute of Molecular Genetics, Czech Academy of Sciences
- Berwini Endaya
- Institute of Biotechnology, Czech Academy of Sciences
- Frantisek Spoutil
- Institute of Molecular Genetics, Czech Academy of Sciences
- Dagmar Zudova
- Institute of Molecular Genetics, Czech Academy of Sciences
- Jan Stursa
- Institute of Biotechnology, Czech Academy of Sciences
- Magdalena Melcova
- Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague
- Zuzana Bielcikova
- General University Hospital
- Lukas Werner
- Institute of Biotechnology, Czech Academy of Sciences
- Jan Prochazka
- Institute of Molecular Genetics, Czech Academy of Sciences
- Radislav Sedlacek
- Institute of Molecular Genetics, Czech Academy of Sciences
- Martina Huttl
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine
- Sona Stemberkova Hubackova
- Institute of Biotechnology, Czech Academy of Sciences
- Martin Haluzik
- Diabetes Centre, Institute for Clinical and Experimental Medicine
- Jiri Neuzil
- Institute of Biotechnology, Czech Academy of Sciences
- DOI
- https://doi.org/10.1038/s41467-022-29486-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Senescent cells play a role in pathogenesis of diabetes, and senolytic agents can improve obesity- and diabetes-related pathologies. Here the authors report that mitochondrially targeted tamoxifen, a potential anti-cancer agent with senolytic activity, alleviates symptoms of obesity and prediabetes in mice, potentially via reduction of food intake and elimination of senescent cells.
